Key result
Emerging observational data suggest sacubitril/valsartan may improve left ventricular ejection fraction and reduce NT-proBNP in patients with cancer therapy-related cardiac dysfunction, warranting prospective clinical trials.
Why the study?
Does sacubitril/valsartan improve cardiac function and outcomes in cancer patients with HFrEF?
Does sacubitril/valsartan improve cardiac function and outcomes in cancer patients with HFrEF?
Sacubitril/valsartan shows encouraging preliminary efficacy in treating cancer therapy-related HFrEF, highlighting the need for dedicated prospective trials in this population.
Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of patients needs to be firmly established. In this issue of Cardio-Oncology, Gregorietti et al. report on the effects of S/V in a small group of cancer patients, primarily women with breast cancer treated with anthracyclines. The data are limited but seem to confirm the encouraging results of prior studies, paving the way to foster the use of S/V in cardio-oncology patients and hopefully, to design ad hoc prospective studies in this highly vulnerable population.
No takes yet. Share an insight, caveat, or question.
Camilli et al. (2020) conducted an editorial in Cancer therapy-related cardiac dysfunction (CTRCD) with HFrEF. Sacubitril/Valsartan was evaluated. Emerging observational data suggest sacubitril/valsartan may improve left ventricular ejection fraction and reduce NT-proBNP in patients with cancer therapy-related cardiac dysfunction, warranting prospective clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: